This report presents the results of a study that dealt specifically with effective communication around the benefit and risk balance of vaccination people’s risk perceptions around vaccines and diseases, and approaches to enhancing communication about the safety and effectiveness of vaccines.
ECDC, DG SANTE and EFSA, supported by a consortium composed of Epiconcept and Integrated Quality Laboratory Services (IQLS), jointly carried out a country visit to Kosovo* from 9 to 13 October 2023, which is part of ECDC’s accession support activities to contribute to the advancement of a One Health approach against antimicrobial resistance (AMR) in the Western Balkans.
This protocol describes a survey undertaken to acquire a snapshot of the distribution of Clostridioides difficile strains in tertiary acute care hospitals in the European Union/European Economic Area (EU/EEA) in 2022–2023
A prolonged genomic cluster of 20 human Listeria monocytogenes ST1607 infections has been reported. The most recent case was reported in March 2024 in Denmark.
This global technical consultation report brings together viewpoints from experts spanning a range of disciplines with the key objective of seeking consensus regarding the terminology used to describe the transmission of pathogens through the air that can potentially cause infection in humans.
A cross-border outbreak of Salmonella Mbandaka ST413 has been ongoing in the European Union/European Economic Area (EU/EEA) and the United Kingdom (UK) for over two years since September 2021.
This reporting protocol is for the 2024 data call for antimicrobial resistance (AMR) surveillance data, collected by the European Antimicrobial Resistance Surveillance Network (EARS-Net) for 2023.
This report summarizes the conclusions of an interview study with public health authorities in Europe and Central Asia, exploring the barriers and drivers to advancing the use of behavioural and cultural insights (BCI) for health.
In 2023, significant increases in the number of measles cases and outbreaks were observed globally, including in 40 of the 53 countries of the European region, and in at least ten EU/EEA countries.
This document assesses the risk associated with the dissemination of carbapenemase-producing hypervirulent Klebsiella pneumoniae (hvKp) of sequence type (ST) 23 and other STs in the European Union/European Economic Area (EU/EEA).